<DOC>
	<DOCNO>NCT00078546</DOCNO>
	<brief_summary>To determine safety combination CD45 monoclonal antibody ( Mab ) follow intravenous injection EBV specific CTL patient nasopharyngeal cancer . To compare expansion , persistence anti-tumor effect EBV specific CTL give CD45 Mab administration observe first study . To obtain preliminary information safety response extend dosage regimen EBV-specific CTL patient , stable disease partial response initial dose EBV-specific CTL .</brief_summary>
	<brief_title>EBV-Specific CTLs Following CD45 Antibody Patients With Epstein-Barr Virus ( EBV ) + Nasopharyngeal Carcinoma ( NPC )</brief_title>
	<detailed_description>Three different dos CTL evaluate : dose level I : 2 x 10e7/m2 ; dose level II : 5 x 10e7/m2 ; dose level III : 1 x 10e8/m2 Day 1 YTH 24/54 800ug/kg 8 hr ; Day 2 YTH 24/54 800ug/kg 8 hr ; Day 3 Rest ; Day 4-6 CTL Infusion ( provide CD45 Mab level &lt; 100 ug/ml ) . Generation EBV-specific CTL After consent separate procurement protocol CTL preparation patient donate 60-70cc peripheral blood . 10-20cc used establishment EBV transform lymphoblastoid cell line ( EBV-LCL ) infection virus produce B95-8 master cell line . The EBV-LCLs take approximately four six week establish . 30-40cc peripheral blood use generate EBV specific CTLs . The CTL line prepare co-cultivation irradiated EBV-LCL patient PBMC . After establishment , CTL line check identity , phenotype microbiological culture cryopreserved prior administration accord SOPs . The antigen specificity CTL line determine cytotoxicity assay possible tetramer reagent . CD45 monoclonal antibody Anti-CD45 combination equal amount ( weight volume ) two monoclonal antibody direct non-overlapping epitope human CD45 . It purify , concentrate , sterile gamma globulin , primarily monomeric IgG , produce supernatant two rat IgG2b hybridoma clone , YTH 24 YTH 54 . The hybridoma produce fusion splenocytes DA rat immunize human leukocyte rat myeloma line Y3 . The combination two MAbs exerts synergistic effect vitro complement-mediated cytotoxicity white cell demonstrate clear almost passenger leukocyte donor kidney transplant . Anti-CD45 Mabs make cGMP condition Therapeutic Antibody Center Oxford Baylor College Medicine pas safety test require FDA . Cell administration Patients pre-medicated Diphenhydramine 1mg/kg IV ( max 50 mg ) Acetaminophen 10mg/kg po ( max 650 mg ) . EBV specific T cell give intravenous injection 1-10 minute either peripheral central line . Outpatients may treat clinic . Monitoring undertaken accord institutional standard administration blood product exception injection give physician . Anti-emetics appropriate dosage patient prescribe necessary . Patients receive supportive care acute chronic toxicity , include blood component antibiotic , intervention appropriate . Antibody administration Patients pre-medicated Diphenhydramine 1mg/kg IV ( max 50 mg ) Acetaminophen 10mg/kg po ( max 650 mg ) . 800ug/kg CD45 Mabs give 2 daily intravenous infusion 8 hour . The antibody aliquot infuse arrive treatment area hand-carried attending physician appoint designate . The antibody aliquot dilute minimal amount normal saline . The resulting solution stable 24 hour . The antibody solution administer syringe pump incremental dos , 0.2-0.8 mg first hour 10 mg/hr thereafter , total infusion time maximum 6 hr . A registered nurse physician must readily available .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Any patient EBV positive NPC , relapse primary resistant disease Life expectancy 6 week . No severe intercurrent infection Patient , parent/guardian able give inform consent Bilirubin le 2x normal SGOT le 3x normal , Hgb high 8.0 g/L Creatinine le 2x normal age Patients investigational therapy one month prior entry study . Karnofsky score equal 50 . Due unknown effect therapy fetus , pregnant woman exclude research . The male partner use condom . Note : Patients would exclude protocol strictly laboratory abnormality include investigator 's discretion approval CCGT Protocol Review Committee FDA reviewer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>EBV</keyword>
	<keyword>NASOPHARYNGEAL</keyword>
	<keyword>CARCINOMA</keyword>
	<keyword>EBV POSITIVE NASOPHARYNGEAL CARCINOMA</keyword>
</DOC>